Global Research Antibodies Market Size By Technology (Western Blotting, Flow Cytometry), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes), By Product (Reagents, Antibodies), By Application (Proteomics, Drug Development), By Geographic Scope And Forecast

Research Antibodies Market Size And Forecast

Research Antibodies Market size was valued at USD 10.87 Billion in 2021 and is projected to reach USD 19.55 Billion by 2030, growing at a CAGR of 6.75% from 2023 to 2030.

The governments are providing huge funds to proteomics and genomics research and that has led to the global Research Antibodies Market growing at a rapid pace. The Global Research Antibodies Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Research Antibodies Market Definition

The proteins which are made up of B cells are called antibodies. These B cells are part of the body’s immune system. The primary function of the antibodies is to latch on to antigens and flag them for destruction. This helps in fighting infection. The research antibodies can bind specific molecules which makes them ideal probes in cell research. Research antibodies are an important tool when it comes to studying protein functions in cells.

Global Research Antibodies Market Overview

The growth of the Global Research Antibodies Market is being driven by increasing research activities. The companies are investing heavily in research and development activities. The growing industry-academia collaboration has also led to the rapid growth of the Global Research Antibodies Market. Emerging markets such as India and China will create new opportunities for the market to grow. However, contrary to the above drivers some restraints will limit the growth of the market. The concerns related to quality and lack of reproducible results will negatively influence the growth of the market.

Global Research Antibodies MarketSegmentation Analysis

The Global Research Antibodies Market is Segmented on the basis of Technology, End User, Product, Application, And Geography.

Research Antibodies Market, By Technology

• Western Blotting
• Flow Cytometry
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunohistochemistry
• Immunofluorescence
• Immunoprecipitation
• Other Technologies

Based on Technology, the market is bifurcated into Western Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and Other Technologies. The flow cytometry segment is dominating the market owing to its ability to perform simultaneous multi-parameter analysis on a single cell within a heterogeneous mixture.

Research Antibodies Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

Based on End User, the market is bifurcated into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organizations. The pharmaceutical and biotechnology companies contributed majorly to the growth of the market as research antibodies are widely being used for drug development.

Research Antibodies Market, By Product

• Reagents
• Antibodies

Based on Product, the market is bifurcated into Reagents and Antibodies. The reagents segment is further bifurcated into Media & Sera, Stains & Dyes, Fixatives, Buffers, Solvents, Enzymes, Probes, and Other Reagents. The antibodies segment is further bifurcated into By Type, By Source, and By Research Area.

Research Antibodies Market, By Application

• Proteomics
• Drug Development
• Genomics

Based on Application, the market is bifurcated into Proteomics, Drug Development, and Genomics. The proteomics segment dominated the market as it was able to effectively minimize the cost, time, and resource requirement for chemical synthesis and biological testing of drugs.

Research Antibodies Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, the Global Research Antibodies Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share of the market will be dominated by North America. The dominance of the North American region is credited to the increasing investment in the development of structure-based drug designs.

Key Players

The “Global Research Antibodies Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific Inc., Merck Group, Abcam PLC, Becton, Dickinson and Company, Cell Signaling Technology, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Danaher Corporation, Lonza, Genscript, Perkinelmer, Inc., Biolegend, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

Partnerships, Collaborations and Agreements

• In 2018, Thermo Fisher Scientific Inc., collaborated with Montreal Neurological Institute with an aim to develop improved and new methods to both characterize and produce antibodies for advanced neurological research associated with Amyotrophic lateral sclerosis, Parkinson’s disease, and other brain diseases.
• In 2020, Thermo Fisher Scientific (US) collaborated with Wuxi and Mayo Clinic To secure FDA authorization for testing COVID-19 with ELISA for detecting both IgM and IgG antibodies.

Mergers and Acquisitions

• On September 2018, Roche announced the acquisition of Tusk Therapeutic Ltd. Tusk is a developer of an antibody that has a novel mode of action aimed at depleting regulatory T cells.
• In 2019, Thermo Fisher Scientific (US) acquired Brammer Bio (US) to expand its capacity for manufacturing viral vectors for gene and cell therapies with Brammer Bio’s CDMO facilities. The acquisition was valued at USD 1.7 billion.

Product Launches and Product Expansions

• On October 2021, Thermo Fisher Scientific, the world leader in serving science, has launched a new CE-IVD-marked COVID-19 test. The TaqPath COVID-19 Fast PCR Combo Kit 2.0. expands Thermo Fisher’s menu of highly accurate tests that detect active SARS-CoV-2 infections.

Report Scope

Top Trending Report